Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of seasonal influenza virus vaccine (NasoVAX)

Next Previous
Trial Profile

Phase II trial of seasonal influenza virus vaccine (NasoVAX)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADhVN120304.H5 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 04 May 2017 According to an Altimmune media release, this study is expected to commence during 3Q of 2017 with initial data expected in 1Q of 2018.
  • 19 Jan 2017 According to a PharmAthene media release, this study is expected to commence during mid-2017 with initial data expected in the fourth quarter of 2017.
  • 24 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top